Continuous process verification is a prospective validation strategy in which ongoing manufacturing is monitored and evaluated using a scientifically sound control strategy. It utilizes development knowledge and process data to provide continued evidence that the process produces products with the specified quality attributes.
Data-driven confirmation during routine operations
Unlike an approach that focuses on a predetermined number of validation batches, continuous process verification considers every suitable production batch as part of the evidence. Critical process parameters, in-process measurements, and critical quality attributes are integrated into a predefined system. The significance is derived not from the volume of data alone, but from the link between the sampling point, process risk, and acceptance criterion.
In tablet manufacturing, for example, moisture at the granulation endpoint, compression force, and active ingredient content can be evaluated as interconnected information. Process Analytical Technology enables measurements during the process; multivariate statistical methods can identify patterns that would remain inconspicuous when viewing individual values. However, the control strategy must define which deviation triggers an investigation, an adjustment, or an interruption.
Prerequisites and ongoing evaluation
The strategy requires that development and scale-up have provided sufficient process understanding. Models, sampling, and measurement methods must be suitable for the intended range, and data from different batches must remain comparable. Changes to raw materials, sensors, software models, or equipment configurations must not go unnoticed and alter the significance of the trend profile.
Regular verification therefore evaluates process capability, shifts, and unusual combinations of parameters. It does not exclude the possibility that individual batches are fully tested; rather, it justifies how in-process controls, release testing, and trend analyses interact. The result can be a confirmation of the established state or the need for additional studies and adjustments to the control strategy.
For the evaluation, not only limit values but also the data architecture and response paths are defined before routine production begins. A sensor value must be assignable to a batch number, a timestamp, the model used, and the respective equipment configuration. Otherwise, it is impossible to decide later whether an observed shift concerns the process, the measurement system, or data processing.
Statistical process control is applied to the process it is intended to represent. If, for example, two manufacturing sites or two granulator sizes are combined, it must be scientifically justified that the data are comparable. Merely achieving an average target value can mask unstable variation; conversely, a single outlier does not mean the process has lost its capability without investigation.
Periodic evaluation may also show that the originally selected measurement frequency should be adjusted. Any change to sampling, the model, or control limits is checked to see if it alters the validation strategy itself.
Distinction from Quality by Design and other process validation
Quality by Design refers to the development approach that examines the quality target product profile, critical attributes, influencing factors, and design space. Continuous process verification is the validation strategy that makes this knowledge usable in commercial or comparably controlled operations. One term therefore explains the scientific derivation, while the other explains the permanent confirmation of the manufacturing process.
In addition to traditional and continuous process verification, Annex 15 also permits a hybrid approach. A hybrid path combines, for example, initially intensively sampled batches with later, ongoing data-based monitoring. In contrast, retrospective validation, which only uses historical batch data after the fact for initial confirmation, is no longer acceptable.
The control strategy only remains robust if the data are evaluated professionally and in a timely manner. A monthly report reflecting outdated trends cannot replace the intended response to a progressive process shift.
Significance for clinical trials
For investigational medicinal products, the manufacturing method may evolve between early batches and later clinical supplies. As soon as process knowledge from development is used for controlled verification, batch data, deviations, and changes must be categorized such that the comparability of the clinical trial medication remains traceable. This particularly concerns parameters with a potential influence on dosing accuracy, release, or sterility.
Full-service CROs like Mediconomics provide support by coordinating CMC documentation, data requirements for batch records, and evaluating comparability in the event of process changes. They can structure interfaces between the manufacturing site, quality assurance, regulatory affairs, and the clinical supply chain so that process data flow into release decisions and regulatory documentation.
Frequently Asked Questions (FAQ)
Does continuous process verification replace batch release testing?
No. It supplements the defined control strategy with ongoing process understanding; the release decisions and specification tests required for the batch remain separate from it.
What data are suitable for continuous process verification?
Suitable data are those whose origin, measurement quality, and relationship to critical process or quality attributes are justified. Pure production KPIs without a quality reference are not sufficient.
When is a hybrid approach useful?
A hybrid approach may be appropriate if a process already has robust development knowledge, but concentrated prospective confirmation is still required for individual process steps.
Regulatory References
- EudraLex Volume 4, Annex 15 “Qualification and Validation” — lists traditional, continuous, and hybrid process verification.
- ICH Q8(R2) “Pharmaceutical Development” — describes development data as the basis for process validation and, where appropriate, continuous verification.
- ICH Q10 “Pharmaceutical Quality System” — covers process performance and product quality throughout the lifecycle.